FDA Expands Inclusion Criteria For WorldHeart LVAS Destination Therapy Trial
This article was originally published in The Gray Sheet
Executive Summary
FDA has given conditional approval for WorldHeart to modify its pivotal trial of the Novacor implantable heart-assist pump. The changes are expected to accelerate the study, which has moved slowly since its start in 2004
You may also be interested in...
Thoratec completes HeartMate PMA
Firm submits the last module of the PMA for its HeartMate II next-generation, rotary-flow left ventricular assist system seeking approval for patients waiting for heart transplants on Dec. 22. The filing is based on data from 133 bridge-to-transplantation patients who used the device from one to 568 days. A trial is ongoing for the device as a destination therapy (1"The Gray Sheet" May 1, 2006, p. 12)...
Thoratec completes HeartMate PMA
Firm submits the last module of the PMA for its HeartMate II next-generation, rotary-flow left ventricular assist system seeking approval for patients waiting for heart transplants on Dec. 22. The filing is based on data from 133 bridge-to-transplantation patients who used the device from one to 568 days. A trial is ongoing for the device as a destination therapy (1"The Gray Sheet" May 1, 2006, p. 12)...
HeartMate II trial fully enrolled
Thoratec completes enrollment for the bridge-to-transplantation arm of its HeartMate II left ventricular assist system, implanting 133 patients. The May 31 announcement notes recent FDA approval to enroll up to 90 additional patients, which Thoratec says will not impact the timing of a planned PMA submission for the device. Enrollment is ongoing for the 200-patient destination therapy arm of the trial comparing HeartMate II with HeartMate XVE in end-stage heart failure patients who don't qualify for a transplant (1"The Gray Sheet" May 1, 2006, p. 12)...